death cross chart , page-6

I will answer this complacent post but will not further engage on this level from here on with you as it is disappointing to have to come this.



Several investors I know personally indeed showed an interest in OBJ due to the P&G partnership.
That is hardly surprising. We discussed the company on several occasions.

Evidently, they have not committed. So much is clear.
The lack of overseas commitment, when OBJ partners in the US as well as in the UK, is actually representing one major criticism from my side.

At this point we should have UK and US investors lurking around and snap up shares on lows, where are they?
Do they honestly miss an entry when an international leader in transdermal delivery partners with the likes of GSK and P&G ?

What is wrong with our story?

I leave that to your optimism.




ESI, same as ADO do have a compelling outlook, so my own research.
This is hardly the place to discuss either.